Eastern canadian colorectal cancer consensus conference 2017

S. F. McGee; W. Alghareeb; C. H. Ahmad; D. Armstrong; S. Babak; S. Berry; J. Biagi; C. Booth; D. Bossé; P. Champion; B. Colwell; N. Finn; R. Goel; S. Gray; J. Green; M. Harb; A. Hyde; A. Jeyakumar; D. Jonker; S. Kanagaratnam; P. Kavan; A. Macmillan; A. Muinuddin; N. Patil; G. Porter; E. Powell; R. Ramjeesingh; M. Raza; S. Rorke; M. Seal; F. Servidio-Italiano; J. Siddiqui; J. Simms; L. Smithson; S. Snow; E. St-Hilaire; T. Stuckless; A. Tate; M. Tehfe; M. Thirlwell; E. Tsvetkova; M. Valdes; M. Vickers; K. Virik; S. Welch; C. Marginean; Timothy Asmis; Dawson; Mahmud

doi:10.3747/co.25.4083

Eastern canadian colorectal cancer consensus conference 2017

S. F. McGee, W. Alghareeb, C. H. Ahmad, D. Armstrong, S. Babak, S. Berry, J. Biagi, C. Booth, D. Bossé, P. Champion, B. Colwell, N. Finn, R. Goel, S. Gray, J. Green, M. Harb, A. Hyde, A. Jeyakumar, D. Jonker, S. KanagaratnamP. Kavan, A. Macmillan, A. Muinuddin, N. Patil, G. Porter, E. Powell, R. Ramjeesingh, M. Raza, S. Rorke, M. Seal, F. Servidio-Italiano, J. Siddiqui, J. Simms, L. Smithson, S. Snow, E. St-Hilaire, T. Stuckless, A. Tate, M. Tehfe, M. Thirlwell, E. Tsvetkova, M. Valdes, M. Vickers, K. Virik, S. Welch, C. Marginean, Timothy Asmis, Dawson, Mahmud

Medicine

Résultat de recherche: Article › examen par les pairs

5 Citations (Scopus)

Résumé

The annual Eastern Canadian Gastrointestinal Cancer Consensus Conference 2017 was held in St. John’s, Newfoundland and Labrador, 28–30 September. Experts in radiation oncology, medical oncology, surgical oncology, and cancer genetics who are involved in the management of patients with gastrointestinal malignancies participated in presentations and discussion sessions for the purpose of developing the recommendations presented here. This consensus statement addresses multiple topics in the management of gastric, rectal, and colon cancer, including identification and management of hereditary gastric and colorectal cancer (CRC); palliative systemic therapy for metastatic gastric cancer; optimum duration of preoperative radiation in rectal cancer—that is, short-compared with long-course radiation; management options for peritoneal carcinomatosis in CRC; implications of tumour location for treatment and prognosis in CRC; and new molecular markers in CRC.

Langue d'origine	English
Pages (de-à)	262-274
Nombre de pages	13
Journal	Current Oncology
Volume	25
Numéro de publication	4
DOI	https://doi.org/10.3747/co.25.4083
Statut de publication	Published - août 2018

Note bibliographique

Funding Information:
We have read and understood Current Oncology’s policy on disclosing conflicts of interest, and we declare the following interests: DA is a member of advisory boards for Celgene and Shire, and has received grants or honoraria from Celgene and Amgen. TA is a member of advisory boards for Amgen, Novartis, Ipsen, Celgene, and Shire, and has received grants or honoraria from Novartis, Roche, and Boehringer Ingelheim. SB is a member of advisory boards for Eli Lilly and Amgen. PC was a one-time advisory board member for AstraZeneca and Merck in 2017, Pfizer and Eli Lilly in 2016, and Celgene, Sanofi, and Boehringer Ingelheim in 2015. BC is a member of advisory boards for Celgene and Novartis, and a member of a speakers bureau for Novartis. SG is a member of advisory boards for Bayer, Roche, Pfizer, Astellas, and Novartis, and her institution has received funding from Bristol–Myers Squibb and Amgen for a clinical trial in which she is listed as an investigator. JG has received grants and honoraria from Novartis. MH is a member of advisory boards for Amgen, Roche, Novartis, Celgene, and Pfizer, and has received grants or honoraria from Novartis and Astellas. DJ’s institution has received funding from AstraZeneca, Bristol–Myers Squibb, Roche, Esperas, Pfizer, Corvus, Turnstone Biologics, Merck, Boston Biomedical, and Array, for clinical trials in which he is listed as an investigator. PK has received grants or honoraria from Pfizer, Celgene, and Shire. EP is a member of advisory boards for Amgen, Novartis, and Genomic Health, and has received grants and honoraria from Roche. RR is a member of a speakers bureau for Astellas, Merck, Roche, Eli Lilly, AstraZeneca, and Bristol–Myers Squibb, and has received grants or honoraria from Celgene, Amgen, and Novartis. MR is a member of advisory boards for, and has received grants or honoraria from, Jensen and Novartis. MS is a member of advisory boards for Shire and Pfizer, and has received grants and honoraria from Amgen. LS is a member of the American College of Surgeons Rural Surgery Advisory Counsel. ESH is a member of advisory boards for Celgene, Bristol–Myers Squibb, Novartis, and Merck.

Publisher Copyright:
© 2018 Multimed Inc.

ASJC Scopus Subject Areas

Oncology

ODD de l’ONU

Cette action contribue à la réalisation des objectifs de développement durable suivants

Accès au document

10.3747/co.25.4083

Autres fichiers et liens

Citer

McGee, S. F., Alghareeb, W., Ahmad, C. H., Armstrong, D., Babak, S., Berry, S., Biagi, J., Booth, C., Bossé, D., Champion, P., Colwell, B., Finn, N., Goel, R., Gray, S., Green, J., Harb, M., Hyde, A., Jeyakumar, A., Jonker, D., ... Mahmud (2018). Eastern canadian colorectal cancer consensus conference 2017. Current Oncology, 25(4), 262-274. https://doi.org/10.3747/co.25.4083

McGee, SF, Alghareeb, W, Ahmad, CH, Armstrong, D, Babak, S, Berry, S, Biagi, J, Booth, C, Bossé, D, Champion, P, Colwell, B, Finn, N, Goel, R, Gray, S, Green, J, Harb, M, Hyde, A, Jeyakumar, A, Jonker, D, Kanagaratnam, S, Kavan, P, Macmillan, A, Muinuddin, A, Patil, N, Porter, G, Powell, E, Ramjeesingh, R, Raza, M, Rorke, S, Seal, M, Servidio-Italiano, F, Siddiqui, J, Simms, J, Smithson, L, Snow, S, St-Hilaire, E, Stuckless, T, Tate, A, Tehfe, M, Thirlwell, M, Tsvetkova, E, Valdes, M, Vickers, M, Virik, K, Welch, S, Marginean, C, Asmis, T, Dawson & Mahmud 2018, 'Eastern canadian colorectal cancer consensus conference 2017', Current Oncology, vol. 25, n° 4, pp. 262-274. https://doi.org/10.3747/co.25.4083

@article{592f36713cdd4dfe8c51704d57548269,

title = "Eastern canadian colorectal cancer consensus conference 2017",

abstract = "The annual Eastern Canadian Gastrointestinal Cancer Consensus Conference 2017 was held in St. John{\textquoteright}s, Newfoundland and Labrador, 28–30 September. Experts in radiation oncology, medical oncology, surgical oncology, and cancer genetics who are involved in the management of patients with gastrointestinal malignancies participated in presentations and discussion sessions for the purpose of developing the recommendations presented here. This consensus statement addresses multiple topics in the management of gastric, rectal, and colon cancer, including identification and management of hereditary gastric and colorectal cancer (CRC); palliative systemic therapy for metastatic gastric cancer; optimum duration of preoperative radiation in rectal cancer—that is, short-compared with long-course radiation; management options for peritoneal carcinomatosis in CRC; implications of tumour location for treatment and prognosis in CRC; and new molecular markers in CRC.",

author = "McGee, {S. F.} and W. Alghareeb and Ahmad, {C. H.} and D. Armstrong and S. Babak and S. Berry and J. Biagi and C. Booth and D. Boss{\'e} and P. Champion and B. Colwell and N. Finn and R. Goel and S. Gray and J. Green and M. Harb and A. Hyde and A. Jeyakumar and D. Jonker and S. Kanagaratnam and P. Kavan and A. Macmillan and A. Muinuddin and N. Patil and G. Porter and E. Powell and R. Ramjeesingh and M. Raza and S. Rorke and M. Seal and F. Servidio-Italiano and J. Siddiqui and J. Simms and L. Smithson and S. Snow and E. St-Hilaire and T. Stuckless and A. Tate and M. Tehfe and M. Thirlwell and E. Tsvetkova and M. Valdes and M. Vickers and K. Virik and S. Welch and C. Marginean and Timothy Asmis and Dawson and Mahmud",

note = "Funding Information: We have read and understood Current Oncology{\textquoteright}s policy on disclosing conflicts of interest, and we declare the following interests: DA is a member of advisory boards for Celgene and Shire, and has received grants or honoraria from Celgene and Amgen. TA is a member of advisory boards for Amgen, Novartis, Ipsen, Celgene, and Shire, and has received grants or honoraria from Novartis, Roche, and Boehringer Ingelheim. SB is a member of advisory boards for Eli Lilly and Amgen. PC was a one-time advisory board member for AstraZeneca and Merck in 2017, Pfizer and Eli Lilly in 2016, and Celgene, Sanofi, and Boehringer Ingelheim in 2015. BC is a member of advisory boards for Celgene and Novartis, and a member of a speakers bureau for Novartis. SG is a member of advisory boards for Bayer, Roche, Pfizer, Astellas, and Novartis, and her institution has received funding from Bristol–Myers Squibb and Amgen for a clinical trial in which she is listed as an investigator. JG has received grants and honoraria from Novartis. MH is a member of advisory boards for Amgen, Roche, Novartis, Celgene, and Pfizer, and has received grants or honoraria from Novartis and Astellas. DJ{\textquoteright}s institution has received funding from AstraZeneca, Bristol–Myers Squibb, Roche, Esperas, Pfizer, Corvus, Turnstone Biologics, Merck, Boston Biomedical, and Array, for clinical trials in which he is listed as an investigator. PK has received grants or honoraria from Pfizer, Celgene, and Shire. EP is a member of advisory boards for Amgen, Novartis, and Genomic Health, and has received grants and honoraria from Roche. RR is a member of a speakers bureau for Astellas, Merck, Roche, Eli Lilly, AstraZeneca, and Bristol–Myers Squibb, and has received grants or honoraria from Celgene, Amgen, and Novartis. MR is a member of advisory boards for, and has received grants or honoraria from, Jensen and Novartis. MS is a member of advisory boards for Shire and Pfizer, and has received grants and honoraria from Amgen. LS is a member of the American College of Surgeons Rural Surgery Advisory Counsel. ESH is a member of advisory boards for Celgene, Bristol–Myers Squibb, Novartis, and Merck. Publisher Copyright: {\textcopyright} 2018 Multimed Inc.",

year = "2018",

month = aug,

doi = "10.3747/co.25.4083",

language = "English",

volume = "25",

pages = "262--274",

journal = "Current Oncology",

issn = "1198-0052",

publisher = "Multimed Inc.",

number = "4",

}

TY - JOUR

T1 - Eastern canadian colorectal cancer consensus conference 2017

AU - McGee, S. F.

AU - Alghareeb, W.

AU - Ahmad, C. H.

AU - Armstrong, D.

AU - Babak, S.

AU - Berry, S.

AU - Biagi, J.

AU - Booth, C.

AU - Bossé, D.

AU - Champion, P.

AU - Colwell, B.

AU - Finn, N.

AU - Goel, R.

AU - Gray, S.

AU - Green, J.

AU - Harb, M.

AU - Hyde, A.

AU - Jeyakumar, A.

AU - Jonker, D.

AU - Kanagaratnam, S.

AU - Kavan, P.

AU - Macmillan, A.

AU - Muinuddin, A.

AU - Patil, N.

AU - Porter, G.

AU - Powell, E.

AU - Ramjeesingh, R.

AU - Raza, M.

AU - Rorke, S.

AU - Seal, M.

AU - Servidio-Italiano, F.

AU - Siddiqui, J.

AU - Simms, J.

AU - Smithson, L.

AU - Snow, S.

AU - St-Hilaire, E.

AU - Stuckless, T.

AU - Tate, A.

AU - Tehfe, M.

AU - Thirlwell, M.

AU - Tsvetkova, E.

AU - Valdes, M.

AU - Vickers, M.

AU - Virik, K.

AU - Welch, S.

AU - Marginean, C.

AU - Asmis, Timothy

AU - Dawson,

AU - Mahmud,

N1 - Funding Information: We have read and understood Current Oncology’s policy on disclosing conflicts of interest, and we declare the following interests: DA is a member of advisory boards for Celgene and Shire, and has received grants or honoraria from Celgene and Amgen. TA is a member of advisory boards for Amgen, Novartis, Ipsen, Celgene, and Shire, and has received grants or honoraria from Novartis, Roche, and Boehringer Ingelheim. SB is a member of advisory boards for Eli Lilly and Amgen. PC was a one-time advisory board member for AstraZeneca and Merck in 2017, Pfizer and Eli Lilly in 2016, and Celgene, Sanofi, and Boehringer Ingelheim in 2015. BC is a member of advisory boards for Celgene and Novartis, and a member of a speakers bureau for Novartis. SG is a member of advisory boards for Bayer, Roche, Pfizer, Astellas, and Novartis, and her institution has received funding from Bristol–Myers Squibb and Amgen for a clinical trial in which she is listed as an investigator. JG has received grants and honoraria from Novartis. MH is a member of advisory boards for Amgen, Roche, Novartis, Celgene, and Pfizer, and has received grants or honoraria from Novartis and Astellas. DJ’s institution has received funding from AstraZeneca, Bristol–Myers Squibb, Roche, Esperas, Pfizer, Corvus, Turnstone Biologics, Merck, Boston Biomedical, and Array, for clinical trials in which he is listed as an investigator. PK has received grants or honoraria from Pfizer, Celgene, and Shire. EP is a member of advisory boards for Amgen, Novartis, and Genomic Health, and has received grants and honoraria from Roche. RR is a member of a speakers bureau for Astellas, Merck, Roche, Eli Lilly, AstraZeneca, and Bristol–Myers Squibb, and has received grants or honoraria from Celgene, Amgen, and Novartis. MR is a member of advisory boards for, and has received grants or honoraria from, Jensen and Novartis. MS is a member of advisory boards for Shire and Pfizer, and has received grants and honoraria from Amgen. LS is a member of the American College of Surgeons Rural Surgery Advisory Counsel. ESH is a member of advisory boards for Celgene, Bristol–Myers Squibb, Novartis, and Merck. Publisher Copyright: © 2018 Multimed Inc.

PY - 2018/8

Y1 - 2018/8

N2 - The annual Eastern Canadian Gastrointestinal Cancer Consensus Conference 2017 was held in St. John’s, Newfoundland and Labrador, 28–30 September. Experts in radiation oncology, medical oncology, surgical oncology, and cancer genetics who are involved in the management of patients with gastrointestinal malignancies participated in presentations and discussion sessions for the purpose of developing the recommendations presented here. This consensus statement addresses multiple topics in the management of gastric, rectal, and colon cancer, including identification and management of hereditary gastric and colorectal cancer (CRC); palliative systemic therapy for metastatic gastric cancer; optimum duration of preoperative radiation in rectal cancer—that is, short-compared with long-course radiation; management options for peritoneal carcinomatosis in CRC; implications of tumour location for treatment and prognosis in CRC; and new molecular markers in CRC.

AB - The annual Eastern Canadian Gastrointestinal Cancer Consensus Conference 2017 was held in St. John’s, Newfoundland and Labrador, 28–30 September. Experts in radiation oncology, medical oncology, surgical oncology, and cancer genetics who are involved in the management of patients with gastrointestinal malignancies participated in presentations and discussion sessions for the purpose of developing the recommendations presented here. This consensus statement addresses multiple topics in the management of gastric, rectal, and colon cancer, including identification and management of hereditary gastric and colorectal cancer (CRC); palliative systemic therapy for metastatic gastric cancer; optimum duration of preoperative radiation in rectal cancer—that is, short-compared with long-course radiation; management options for peritoneal carcinomatosis in CRC; implications of tumour location for treatment and prognosis in CRC; and new molecular markers in CRC.

UR - http://www.scopus.com/inward/record.url?scp=85055084956&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055084956&partnerID=8YFLogxK

U2 - 10.3747/co.25.4083

DO - 10.3747/co.25.4083

M3 - Article

C2 - 30111967

AN - SCOPUS:85055084956

SN - 1198-0052

VL - 25

SP - 262

EP - 274

JO - Current Oncology

JF - Current Oncology

IS - 4

ER -

Eastern canadian colorectal cancer consensus conference 2017

Résumé

Note bibliographique

ASJC Scopus Subject Areas

ODD de l’ONU

Accès au document

Autres fichiers et liens

Empreinte numérique

Citer